{
    "2021-04-21": [
        [
            {
                "time": "2021-04-21",
                "original_text": "智飞生物（300122）：代理产品和自主产品放量推动Q1业绩高增，新冠疫苗Q2有望大幅贡献业绩",
                "features": {
                    "keywords": [
                        "智飞生物",
                        "代理产品",
                        "自主产品",
                        "Q1业绩高增",
                        "新冠疫苗",
                        "Q2贡献业绩"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-04-21",
                "original_text": "一季度高仓位运作，银华基金李晓星4000字长文谈投资逻辑",
                "features": {
                    "keywords": [
                        "一季度高仓位",
                        "银华基金",
                        "李晓星",
                        "投资逻辑"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "2021-04-21",
                "original_text": "9成盈利、54家业绩翻番：基金增持，医药股掀涨停潮",
                "features": {
                    "keywords": [
                        "9成盈利",
                        "54家业绩翻番",
                        "基金增持",
                        "医药股",
                        "涨停潮"
                    ],
                    "sentiment_score": 0.95,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-04-21",
                "original_text": "粤开医药研究|网售处方药全面放开，第五批带量采购箭在弦上",
                "features": {
                    "keywords": [
                        "网售处方药",
                        "全面放开",
                        "第五批带量采购",
                        "医药研究"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-04-21",
                "original_text": "渤海证券-医药行业周报：药品与耗材国采推进，结合估值与业绩探寻机会【行业研究】",
                "features": {
                    "keywords": [
                        "渤海证券",
                        "医药行业周报",
                        "药品与耗材国采",
                        "估值与业绩"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-04-21",
                "original_text": "国元证券-智飞生物年报&2021Q1季报点评：业绩实现高速增长，“自研+代理”两开花【公司研究】",
                "features": {
                    "keywords": [
                        "国元证券",
                        "智飞生物",
                        "年报",
                        "季报点评",
                        "业绩高速增长",
                        "自研+代理"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-04-21",
                "original_text": "八大券商主题策略：A股医药行业龙头名单精选 这些都是核心赛道！",
                "features": {
                    "keywords": [
                        "八大券商",
                        "A股医药行业",
                        "龙头名单",
                        "核心赛道"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "2021-04-21",
                "original_text": "平安证券-智飞生物：2020保持快速增长，2021等待新冠苗放量、微卡获批【公司研究】",
                "features": {
                    "keywords": [
                        "平安证券",
                        "智飞生物",
                        "2020快速增长",
                        "2021新冠苗放量",
                        "微卡获批"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-04-21",
                "original_text": "【医药】药品耗材国采持续推进，医改稳态化下结合业绩寻机会――医药行业周报—―中性",
                "features": {
                    "keywords": [
                        "药品耗材国采",
                        "医改稳态化",
                        "业绩寻机会",
                        "医药行业周报"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-04-21",
                "original_text": "东吴证券-智飞生物：业绩超市场预期，新冠疫苗业绩兑现再即【公司研究】",
                "features": {
                    "keywords": [
                        "东吴证券",
                        "智飞生物",
                        "业绩超预期",
                        "新冠疫苗",
                        "业绩兑现"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-04-21",
                "original_text": "疫苗板块持续走高，康华生物大涨8%",
                "features": {
                    "keywords": [
                        "疫苗板块",
                        "康华生物",
                        "大涨8%"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-04-21",
                "original_text": "看好医药股明星基金一季度增持",
                "features": {
                    "keywords": [
                        "医药股",
                        "明星基金",
                        "一季度增持"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-04-21",
                "original_text": "中原晨会0421】医药行业月报、市场分析、亿纬锂能年报点评、农林牧渔行业周报、汽车行业中报、光线传媒年报点评",
                "features": {
                    "keywords": [
                        "中原晨会",
                        "医药行业月报",
                        "市场分析",
                        "亿纬锂能年报",
                        "农林牧渔行业周报",
                        "汽车行业中报",
                        "光线传媒年报"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "2021-04-21",
                "original_text": "智飞生物2020年年报及2021年一季报点评：业绩超市场预期，新冠疫苗业绩兑现再即",
                "features": {
                    "keywords": [
                        "智飞生物",
                        "2020年报",
                        "2021一季报",
                        "业绩超预期",
                        "新冠疫苗",
                        "业绩兑现"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}